For example, the combination of PD‐1/PD‐L1 and CTLA‐4 inhibitors has demonstrated enhanced efficacy across multiple cancer types.[329, 330, 331, 332] Studies have shown that anti‐CTLA‐4 and anti‐PD‐1 checkpoint blockades target distinct subsets of TILs,[333, 334] and their synergistic effects lead to increased T cell infiltration and sustained anti‐tumor immune responses. The gene discussed is PDCD1; the disease is cancer.